Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts:: Relation to drug uptake and cell membrane fluidity

被引:18
作者
Przybylska, M [1 ]
Koceva-Chyla, A [1 ]
Rózga, B [1 ]
Józwiak, Z [1 ]
机构
[1] Univ Lodz, Inst Biophys, Dept Thermobiol, PL-90237 Lodz, Poland
关键词
Down's syndrome; fibroblasts; daunorubicin; cytotoxicity; intracellular accumulation; cell membrane fluidity; TMA-DPH; 12; AS;
D O I
10.1006/cbir.2000.0583
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The influence of daunorubicin (DNR) on survival of human normal (S-126) and trisomic, with respect to chromosome 21 (T-164; S-240), skin fibroblasts and some parameters related to it, such as intracellular drug accumulation, distribution and interaction with cell membrane, were studied. The in vitro growth-inhibition assay indicated that DNR was less cytotoxic for trisomic than for normal cells. Comparison of kinetic parameters and intracellular distribution of this compound showed that the uptake and the amount of intracellular free DNR were greater in normal than in trisomic cells. Contrary to this, there were no significant differences between the amount of DNA-bound drug in both types of cells. TMA-DPH and 12-AS fluorescence anisotropy measurements demonstrated that DNR decreased lipid fluidity in the inner hydrophobic region of plasma membrane in both cell types, but did not influence the fluidity of the outer surface of membrane. We conclude that fibroblasts derived from individuals affected with Down's syndrome are better protected from the damage induced by DNR than normal cells. (C) 2001 Academic Press.
引用
收藏
页码:157 / 170
页数:14
相关论文
共 97 条
[1]   CHARACTERIZATION OF DAUNORUBICIN RESISTANCE IN K562 LEUKEMIA-CELLS LACKING DAUNORUBICIN REDUCTASE-ACTIVITY [J].
AHMED, NK ;
VASANTHAKUMAR, G .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (09) :1329-+
[2]   FLUOROMETRIC-DETERMINATION OF THE KINETICS OF ANTHRACYCLINES UPTAKE BY CELLS [J].
ANDREONI, A ;
COLASANTI, A ;
KISSLINGER, A ;
MASTROCINQUE, M ;
RICCIO, P ;
ROBERTI, G .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 1994, 28 (01) :53-68
[3]   Kinetic transport analysis of daunorubicin by LoVo and LoVo/DX cells [J].
Andreoni, A ;
Colasanti, A ;
Colasanti, P ;
Kisslinger, A ;
Mastrocinque, M ;
Riccio, P ;
Roberti, G .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1996, 64 (01) :159-162
[4]  
[Anonymous], CANC CHEMOTHERAPY BI
[5]   CELL-MEMBRANES AS TARGET FOR ANTICANCER AGENTS [J].
ARANCIA, G ;
DONELLI, G .
PHARMACOLOGICAL RESEARCH, 1991, 24 (03) :205-217
[6]   Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction [J].
Ax, W ;
Soldan, M ;
Koch, L ;
Maser, E .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (03) :293-300
[7]  
BATIST G, 1986, J BIOL CHEM, V261, P5544
[8]  
BENSON PF, 1975, LANCET, V1, P584
[9]  
BERGER R, 1982, HUM GENE MAPPING, V6, P205
[10]  
Brugge K L, 1992, EXS, V62, P190